Several companies that manufacture generic drugs are talking with the Department of Justice to avoid indictments for allegedly colluding to raise their prices. They would pay fines and admit that some allegations are true, Bloomberg reports.
The big picture: These potential "deferred prosecution agreements" would only cover the federal probe, not the state-led antitrust investigation, but it could shed light on any price fixing that occurred in the generic drug marketplace.
